Central ObesityNCT07486557
Cistanche Deserticola Extract Combined With Aerobic Exercise Improves Body Composition, Insulin Resistance and Inflammation in Men With Central Obesity
A study testing Supervised Aerobic Exercise and Cistanche deserticola Extract in people with Central Obesity and Insulin Resistance, run by Beijing Sport University at 1 site in China.
Trial summary
This is a randomized controlled trial to see if a combination of aerobic exercise and Cistanche deserticola extract can improve body composition, insulin resistance, and inflammation in men with central obesity. Read more about this study
- Who is it for?
- Ages 50 to 55 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Central Obesity, Insulin Resistance, Inflammation
- What is being tested?
- Supervised Aerobic Exercise and Cistanche deserticola Extract
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 125 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2025to 1 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 55 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Chinese males aged 50 to 55 years.
- Central obesity, defined as a waist circumference (WC) > 90 cm and a body mass index (BMI) ≥ 25.0 kg/m².
- A daily eating window of ≥ 14 hours.
- Moderate-to-vigorous physical activity (MVPA) ≤ 150 minutes per week.
- Sedentary time ≥ 8 hours per day.
Who cannot join
- Confirmed diagnosis of cardiovascular disease (CVD) or diabetes mellitus.
- A history of alcohol consumption or tobacco use.
- Diagnosis of conditions (e.g., arthritis) or presence of injuries that impair gait and limit exercise capacity.
- Participation in other clinical trials within 4 weeks prior to enrollment.
- Use of treatments or medications that may affect appetite or metabolism.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Cistanche Deserticola Extract Combined With Aerobic Exercise Improves Body Composition, Insulin Resistance and Inflammation in Men With Central Obesity: a Randomized Controlled Trial
This is a randomized controlled trial to see if a combination of aerobic exercise and Cistanche deserticola extract can improve body composition, insulin resistance, and inflammation in men with central obesity. Participants will be randomly assigned to either an intervention group (18 weeks of supervised aerobic exercise plus daily Cistanche extract supplementation) or a control group (usual lifestyle advice). The investigators will measure changes in body fat percentage, muscle mass, blood sugar, insulin levels, and inflammatory markers before and after the 18-week intervention. The goal is to find a safe and effective way to help men with central obesity improve their metabolic health. Possible benefits include better body composition and improved insulin sensitivity. Potential risks are mild muscle soreness or digestive discomfort from the supplement.
- Conditions
- Central Obesity, Insulin Resistance, Inflammation
- Being tested
- Supervised Aerobic Exercise, Cistanche deserticola Extract
- Keywords
- Aerobic Exercise, Cistanche deserticola, Body Composition, Insulin Resistance, Inflammation
- Medical subject headings
- Obesity, Abdominal, Insulin Resistance, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Supervised Aerobic ExerciseBehavioural
Moderate-intensity aerobic exercise 3 times per week, 40 minutes per session, for 18 weeks, supervised by trained exercise professionals.
Cistanche deserticola ExtractDietary supplement
Daily oral supplementation with standardized Cistanche deserticola extract for 18 weeks, administered as a capsule or powder.
| Study group | Role | What they receive |
|---|---|---|
| Control Group (CON) | No intervention | Not described |
| Cistanche deserticola Group (CD) | Experimental | Not described Receives: Dietary Supplement: Cistanche deserticola Extract |
| Aerobic Exercise Training Group (ET) | Experimental | Not described Receives: Behavioral: Supervised Aerobic Exercise |
| Combined Intervention Group (CDET) | Experimental | Not described Receives: Behavioral: Supervised Aerobic Exercise; Dietary Supplement: Cistanche deserticola Extract |
What is being measured
The primary outcome is the main question the study is designed to answer.
Waist Circumference
Full Name of Measurement Tool：Lufkin W606PM Metallic Tape；Measurement Method：Measured in accordance with the guidelines of the International Society for the Advancement of Kinanthropometry (ISAK). The measurement site is the midpoint between the iliac crest and the lower costal margin. The subject stands with relaxed abdomen and feet together, and the measurement is repeated at least 3 times to take the average value；Measurement Unit：Centimeter (cm)
Measured: Baseline to 18 weeks
Height
Full Name of Measurement Tool：Seca Leicester Stadiometer；Measurement Method：Measured in a standard standing position, barefoot, with the back against the stadiometer and the head kept level；Measurement Unit：Centimeter (cm)
Measured: Baseline to 18 weeks
Body Weight
Full Name of Measurement Tool：Tanita MC-780 MA Bioelectrical Impedance Analysis Instrument；Measurement Method：Measured after fasting, with light clothing and empty bladder, the measurement is repeated at least 3 times to take the average value；Measurement Unit：Kilogram (kg)
Measured: Baseline to 18 weeks
Body Mass Index (BMI)
Full Name of Measurement Tool：Seca Leicester Stadiometer + Tanita MC-780 MA Bioelectrical Impedance Analysis Instrument；Measurement Method：Calculated by the formula: BMI = Body Weight (kg) / Height² (m²)；Measurement Unit：Kilogram per square meter (kg/m²)
Measured: Baseline to 18 weeks
Systolic Blood Pressure (SBP)
Full Name of Measurement Tool：Omron M7 Intelli IT Automatic Blood Pressure Monitor；Measurement Method：Measured in a standard sitting position after the subject rests for 15 minutes, the measurement is repeated 3 times to take the average value；Measurement Unit：Millimeter of mercury (mmHg)
Measured: Baseline to 18 weeks
Diastolic Blood Pressure (DBP)
Full Name of Measurement Tool：Omron M7 Intelli IT Automatic Blood Pressure Monitor；Measurement Method：Measured in a standard sitting position after the subject rests for 15 minutes, the measurement is repeated 3 times to take the average value；Measurement Unit：Millimeter of mercury (mmHg)
Measured: Baseline to 18 weeks
Body Fat Percentage
Full Name of Measurement Tool：Tanita MC-780 MA Bioelectrical Impedance Analysis Instrument；Measurement Method：Measured after more than 10 hours of fasting and avoiding exercise, alcohol and caffeine for more than 4 hours. The skin electrodes are cleaned before measurement, and the measurement is repeated 3 times to take the average value；Measurement Unit：Percentage (%)
Measured: Baseline to 18 weeks
Muscle Mass Percentage
Full Name of Measurement Tool：Tanita MC-780 MA Bioelectrical Impedance Analysis Instrument；Measurement Method：Measured after more than 10 hours of fasting and avoiding exercise, alcohol and caffeine for more than 4 hours. The skin electrodes are cleaned before measurement, and the measurement is repeated 3 times to take the average value；Measurement Unit：Percentage (%)
Measured: Baseline to 18 weeks
Maximal Oxygen Consumption (VO₂max)
Full Name of Measurement Tool：Treadmill + Physio-Dyne Instrument Corp. MAX II Metabolic System + Polar H10 Heart Rate Monitor；Measurement Method：The modified Bruce protocol is adopted, the treadmill is subjected to incremental load exercise until exhaustion, and respiratory gas exchange variables and heart rate are recorded in real time；Measurement Unit：Milliliter per kilogram per minute (mL/kg/min)
Measured: Baseline to 18 weeks
Secondary outcomes (17)
Fasting Blood Glucose
Full Name of Measurement Tool：Bayer AG Contour Plus Blood Glucose Meter；Measurement Method：Venous blood is collected after the subject fasts for 10 hours and detected immediately；Measurement Unit：Millimole per liter (mmol/L)
Measured: Baseline to 18 weeks
Glycated Hemoglobin (HbA1c)
Full Name of Measurement Tool：Roche cobas® b 101 Analyzer；Measurement Method：Venous blood is collected on an empty stomach, and serum is separated for instrument detection；Measurement Unit：Percentage (%)
Measured: Baseline to 18 weeks
Fasting Insulin
Full Name of Measurement Tool：Mercodia Uppsala Enzyme-Linked Immunosorbent Assay (ELISA) Kit；Measurement Method：Venous blood is collected on an empty stomach, plasma is separated and detected by double replicate ELISA；Measurement Unit：Milliunit per liter (mU/L)
Measured: Baseline to 18 weeks
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Full Name of Measurement Tool：Bayer AG Contour Plus Blood Glucose Meter + Mercodia Uppsala Enzyme-Linked Immunosorbent Assay (ELISA) Kit；Measurement Method：Calculated by the formula: HOMA-IR = (Fasting Blood Glucose × Fasting Insulin) / 22.5；Measurement Unit：No unit
Measured: Baseline to 18 weeks
Homeostatic Model Assessment for Beta Cell Function (HOMA-β)
Full Name of Measurement Tool：Bayer AG Contour Plus Blood Glucose Meter + Mercodia Uppsala Enzyme-Linked Immunosorbent Assay (ELISA) Kit；Measurement Method：Calculated by the formula: HOMA-β = (20 × Fasting Insulin) / (Fasting Blood Glucose - 3.5)；Measurement Unit：No unit
Measured: Baseline to 18 weeks
Total Cholesterol (TC)
Full Name of Measurement Tool：Roche cobas® c 111 Analyzer；Measurement Method：Venous blood is collected on an empty stomach, and serum is separated for instrument detection；Measurement Unit：Millimole per liter (mmol/L)
Measured: Baseline to 18 weeks
Triglycerides (TG)
Full Name of Measurement Tool：Roche cobas® c 111 Analyzer；Measurement Method：Venous blood is collected on an empty stomach, and serum is separated for instrument detection；Measurement Unit：Millimole per liter (mmol/L)
Measured: Baseline to 18 weeks
High-Density Lipoprotein (HDL)
Full Name of Measurement Tool：Roche cobas® c 111 Analyzer；Measurement Method：Venous blood is collected on an empty stomach, and serum is separated for instrument detection；Measurement Unit：Millimole per liter (mmol/L)
Measured: Baseline to 18 weeks
Low-Density Lipoprotein (LDL)
Full Name of Measurement Tool：Roche cobas® c 111 Analyzer；Measurement Method：Venous blood is collected on an empty stomach, and serum is separated for instrument detection；Measurement Unit：Millimole per liter (mmol/L)
Measured: Baseline to 18 weeks
Leptin
Full Name of Measurement Tool：ImmunoDiagnostics Limited / Thermo Fisher Scientific Enzyme-Linked Immunosorbent Assay (ELISA) Kit；Measurement Method：Venous blood is collected on an empty stomach, plasma is separated and detected by double replicate ELISA；Measurement Unit：Nanogram per milliliter (ng/ml)
Measured: Baseline to 18 weeks
Ghrelin
Full Name of Measurement Tool：Bio-Rad Hercules California Luminex Assay Kit；Measurement Method：Venous blood is collected on an empty stomach, plasma is separated and detected by magnetic bead-based Luminex assay；Measurement Unit：Picogram per milliliter (pg/ml)
Measured: Baseline to 18 weeks
C-Reactive Protein (CRP)
Full Name of Measurement Tool：ImmunoDiagnostics Limited / Thermo Fisher Scientific Enzyme-Linked Immunosorbent Assay (ELISA) Kit；Measurement Method：Venous blood is collected on an empty stomach, plasma is separated and detected by double replicate ELISA；Measurement Unit：Microgram per milliliter (ug/ml)
Measured: Baseline to 18 weeks
Plasminogen Activator Inhibitor-1 (PAI-1)
Full Name of Measurement Tool：Bio-Rad Hercules California Luminex Assay Kit；Measurement Method：Venous blood is collected on an empty stomach, plasma is separated and detected by magnetic bead-based Luminex assay；Measurement Unit：Picogram per milliliter (pg/ml)
Measured: Baseline to 18 weeks
Gut Microbiota Composition (Phylum/Class/Genus level)
Full Name of Measurement Tool：Omega BIO-TEK Norcross E.Z.N.A.® Stool DNA Kit + BGI Genomics 16S/18S/ITS Amplicon Metagenomic Sequencing Platform；Measurement Method：Fecal samples are provided by subjects on an empty stomach, transported on ice within 2 hours or frozen at -80℃; microbial DNA is extracted for 16S rRNA amplicon sequencing, and taxonomic composition is analyzed by software such as DADA2 and phyloseq；Measurement Unit：Relative abundance (%) / No unit (sequencing read count)
Measured: Baseline to 18 weeks
Microbial Differential Abundance (Enterocloster/Gemella)
Full Name of Measurement Tool：BGI Genomics 16S/18S/ITS Amplicon Metagenomic Sequencing Platform + R Language (emmeans/vegan package)；Measurement Method：Analyzed by Δabundance (post-intervention - pre-intervention), combined with Analysis of Covariance (ANCOVA) and Permutational Multivariate Analysis of Variance (PERMANOVA) statistical tests；Measurement Unit：No unit (standardized abundance value)
Measured: Baseline to 18 weeks
Short-Chain Fatty Acids (SCFAs) Targeted Metabolomics Detection
Full Name of Measurement Tool：Thermo ScientificTM TSQ Altis Mass Spectrometer + Thermo Scientific Vanquish TM Flex Ultra-High Performance Liquid Chromatograph + Waters ACQUITY UPLC BEH C18 Chromatographic Column；Measurement Method：Prepare SCFA standards and isotope internal standards, extract biological sample metabolites. UHPLC-MS/MS detection with gradient elution (40°C, 2μL injection, 0.3mL/min flow rate), ESI negative ion MRM mode; validate via linearity, precision, accuracy, stability and QC. Quantify with standard/internal standard ratio standard curve; conduct PCA, clustering, KEGG annotation and differential metabolite screening；Measurement Unit：nanogram per milliliter (ng/mL) / microgram per milliliter (ug/mL)
Measured: Baseline to 18 weeks
Total Daily Energy Intake
Full Name of Measurement Tool：Dietary Record（MyFitnessPal APP）； trained dietitians calculate total daily energy intake using nutrient databases; compliance is assessed during study visits；Measurement Unit：Kilocalorie per day (kcal/d)
Measured: Baseline to 18 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2026
- Study start1 Jun 2025
- Primary completion1 Mar 2026
- Study completion1 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Central ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 125 participants (actual)
Sponsor and investigators
- Lead sponsor
- Beijing Sport University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07486557
- Sponsor's protocol ID
- IRB-2025073
- Status last verified
- Jun 2025
- First submitted
- 11 Mar 2026
- Last updated
- 20 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cistanche Deserticola Extract Combined With Aerobic Exercise Improves Body Composition, Insulin Resistance and Inflammation in Men With Central Obesity: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07486557
- Acronym / sponsor ID
- IRB-2025073
- Conditions
- Central Obesity, Insulin Resistance, Inflammation
- Keywords
- Aerobic Exercise, Cistanche deserticola, Body Composition, Insulin Resistance, Inflammation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 125 participants (actual)
- Lead sponsor
- Beijing Sport UniversityUniversity, hospital or other
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 1 Mar 2026 (actual)
- Study completion
- 1 Mar 2026 (actual)
- First posted
- 20 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized controlled trial to see if a combination of aerobic exercise and Cistanche deserticola extract can improve body composition, insulin resistance, and inflammation in men with central obesity. Participants will be randomly assigned to either an intervention group (18 weeks of supervised aerobic exercise plus daily Cistanche extract supplementation) or a control group (usual lifestyle advice). The investigators will measure changes in body fat percentage, muscle mass, blood sugar, insulin levels, and inflammatory markers before and after the 18-week intervention. The goal is to find a safe and effective way to help men with central obesity improve their metabolic health. Possible benefits include better body composition and improved insulin sensitivity. Potential risks are mild muscle soreness or digestive discomfort from the supplement.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Control Group (CON) | No intervention | – |
| Cistanche deserticola Group (CD) | Experimental | Dietary Supplement: Cistanche deserticola Extract |
| Aerobic Exercise Training Group (ET) | Experimental | Behavioral: Supervised Aerobic Exercise |
| Combined Intervention Group (CDET) | Experimental | Behavioral: Supervised Aerobic Exercise, Dietary Supplement: Cistanche deserticola Extract |
Who may qualify
- Ages
- 50 to 55 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Chinese males aged 50 to 55 years.
- Central obesity, defined as a waist circumference (WC) > 90 cm and a body mass index (BMI) ≥ 25.0 kg/m².
- A daily eating window of ≥ 14 hours.
- Moderate-to-vigorous physical activity (MVPA) ≤ 150 minutes per week.
- Sedentary time ≥ 8 hours per day.
Key exclusion criteria (5 listed)
- Confirmed diagnosis of cardiovascular disease (CVD) or diabetes mellitus.
- A history of alcohol consumption or tobacco use.
- Diagnosis of conditions (e.g., arthritis) or presence of injuries that impair gait and limit exercise capacity.
- Participation in other clinical trials within 4 weeks prior to enrollment.
- Use of treatments or medications that may affect appetite or metabolism.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Supervised Aerobic ExerciseModerate-intensity aerobic exercise 3 times per week, 40 minutes per session, for 18 weeks, supervised by trained exercise professionals. | Behavioural | Aerobic Exercise Training Group (ET), Combined Intervention Group (CDET) |
| Cistanche deserticola ExtractDaily oral supplementation with standardized Cistanche deserticola extract for 18 weeks, administered as a capsule or powder. | Dietary supplement | Cistanche deserticola Group (CD), Combined Intervention Group (CDET) |
Primary outcome
Waist Circumference
Time frame: Baseline to 18 weeks
Full Name of Measurement Tool：Lufkin W606PM Metallic Tape；Measurement Method：Measured in accordance with the guidelines of the International Society for the Advancement of Kinanthropometry (ISAK). The measurement site is the midpoint between the iliac crest and the lower costal margin. The subject stands with relaxed abdomen and feet together, and the measurement is repeated at least 3 times to take the average value；Measurement Unit：Centimeter (cm)
Height
Time frame: Baseline to 18 weeks
Full Name of Measurement Tool：Seca Leicester Stadiometer；Measurement Method：Measured in a standard standing position, barefoot, with the back against the stadiometer and the head kept level；Measurement Unit：Centimeter (cm)
Body Weight
Time frame: Baseline to 18 weeks
Full Name of Measurement Tool：Tanita MC-780 MA Bioelectrical Impedance Analysis Instrument；Measurement Method：Measured after fasting, with light clothing and empty bladder, the measurement is repeated at least 3 times to take the average value；Measurement Unit：Kilogram (kg)
Body Mass Index (BMI)
Time frame: Baseline to 18 weeks
Full Name of Measurement Tool：Seca Leicester Stadiometer + Tanita MC-780 MA Bioelectrical Impedance Analysis Instrument；Measurement Method：Calculated by the formula: BMI = Body Weight (kg) / Height² (m²)；Measurement Unit：Kilogram per square meter (kg/m²)
Systolic Blood Pressure (SBP)
Time frame: Baseline to 18 weeks
Full Name of Measurement Tool：Omron M7 Intelli IT Automatic Blood Pressure Monitor；Measurement Method：Measured in a standard sitting position after the subject rests for 15 minutes, the measurement is repeated 3 times to take the average value；Measurement Unit：Millimeter of mercury (mmHg)
Diastolic Blood Pressure (DBP)
Time frame: Baseline to 18 weeks
Full Name of Measurement Tool：Omron M7 Intelli IT Automatic Blood Pressure Monitor；Measurement Method：Measured in a standard sitting position after the subject rests for 15 minutes, the measurement is repeated 3 times to take the average value；Measurement Unit：Millimeter of mercury (mmHg)
Body Fat Percentage
Time frame: Baseline to 18 weeks
Full Name of Measurement Tool：Tanita MC-780 MA Bioelectrical Impedance Analysis Instrument；Measurement Method：Measured after more than 10 hours of fasting and avoiding exercise, alcohol and caffeine for more than 4 hours. The skin electrodes are cleaned before measurement, and the measurement is repeated 3 times to take the average value；Measurement Unit：Percentage (%)
Muscle Mass Percentage
Time frame: Baseline to 18 weeks
Full Name of Measurement Tool：Tanita MC-780 MA Bioelectrical Impedance Analysis Instrument；Measurement Method：Measured after more than 10 hours of fasting and avoiding exercise, alcohol and caffeine for more than 4 hours. The skin electrodes are cleaned before measurement, and the measurement is repeated 3 times to take the average value；Measurement Unit：Percentage (%)
Maximal Oxygen Consumption (VO₂max)
Time frame: Baseline to 18 weeks
Full Name of Measurement Tool：Treadmill + Physio-Dyne Instrument Corp. MAX II Metabolic System + Polar H10 Heart Rate Monitor；Measurement Method：The modified Bruce protocol is adopted, the treadmill is subjected to incremental load exercise until exhaustion, and respiratory gas exchange variables and heart rate are recorded in real time；Measurement Unit：Milliliter per kilogram per minute (mL/kg/min)
17 secondary outcomes
Fasting Blood Glucose
Time frame: Baseline to 18 weeks
Glycated Hemoglobin (HbA1c)
Time frame: Baseline to 18 weeks
Fasting Insulin
Time frame: Baseline to 18 weeks
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Time frame: Baseline to 18 weeks
Homeostatic Model Assessment for Beta Cell Function (HOMA-β)
Time frame: Baseline to 18 weeks
Total Cholesterol (TC)
Time frame: Baseline to 18 weeks
Triglycerides (TG)
Time frame: Baseline to 18 weeks
High-Density Lipoprotein (HDL)
Time frame: Baseline to 18 weeks
Low-Density Lipoprotein (LDL)
Time frame: Baseline to 18 weeks
Leptin
Time frame: Baseline to 18 weeks
Ghrelin
Time frame: Baseline to 18 weeks
C-Reactive Protein (CRP)
Time frame: Baseline to 18 weeks
Plasminogen Activator Inhibitor-1 (PAI-1)
Time frame: Baseline to 18 weeks
Gut Microbiota Composition (Phylum/Class/Genus level)
Time frame: Baseline to 18 weeks
Microbial Differential Abundance (Enterocloster/Gemella)
Time frame: Baseline to 18 weeks
Short-Chain Fatty Acids (SCFAs) Targeted Metabolomics Detection
Time frame: Baseline to 18 weeks
Total Daily Energy Intake
Time frame: Baseline to 18 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Central Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Not yet recruiting
Compulsive Eating and Brain's Reward System in Different Pathologies
PARKINSON DISEASE (Disorder), Bipolar 1 Disorder
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Active, not recruiting
Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery
COPD Exacerbation, Oxygen Toxicity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Supervised Aerobic Exercise and Cistanche deserticola Extract in people with Central Obesity and Insulin Resistance, run by Beijing Sport University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Waist Circumference (time frame: Baseline to 18 weeks). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026.